Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 3 - What They Never Told You

What 5 Analyst Ratings Have To Say About Vertex Pharmaceuticals

Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

2 Recession Stocks to Buy Right Now

2 Recession Stocks to Buy Right Now

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

Analyst Ratings for Vertex Pharmaceuticals

Analyst Ratings for Vertex Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analyzing Vertex Pharmaceuticals's Short Interest

Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has risen 18.8% since its last report. The company recently reported that it has 4.01 million shares sold short, which is 1.58% of all regular shares that are available for trading.

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 6.39% on an annualized basis producing an average annual return of 17.51%. Currently, Vertex Pharmaceuticals has a market capitalization of $65.74 billion.

Why Vertex Pharmaceuticals Shares Are Falling

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do

inkl

Read news from The Economist, FT, and more,
with one subscription

If You Invested $1000 In Vertex Pharmaceuticals 15 Years Ago, Here's How Much You Would Have Today

If You Invested $1000 In Vertex Pharmaceuticals 15 Years Ago, Here's How Much You Would Have Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.29% on an annualized basis producing an average annual return of 15.84%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.91 billion.

$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much

$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 7.35% on an annualized basis producing an average annual return of 15.26%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.63 billion.

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548. One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.35% on an annualized basis.

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.

Recap: Vertex Pharmaceuticals Q4 Earnings

Recap: Vertex Pharmaceuticals Q4 Earnings

Vertex Pharmaceuticals (NASDAQ:VRTX) reported its Q4 earnings results on Wednesday, January 26, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Where Vertex Pharmaceuticals Stands With Analysts

Where Vertex Pharmaceuticals Stands With Analysts

Over the past 3 months, 6 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Get all your
news in one place.

100's of premium titles.
One news app.

1 2 3

Organisations

US Federal Reserve

B of A Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play